Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - EMMAUS LIFE SCIENCES, INC. | a17-17113_1ex99d1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): July 7, 2017
Emmaus Life Sciences, Inc.
(Exact Name of Registrant as Specified in Its Charter)
|
Delaware |
|
000-53072 |
|
41-2254389 |
|
(State or Other Jurisdiction of |
|
(Commission File Number) |
|
(IRS Employer |
21250 Hawthorne Boulevard, Suite 800, Torrance, CA 90503
(Address, including zip code, off principal executive offices)
Registrant’s telephone number, including area code 310-214-0065
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
Large accelerated filer o |
|
Accelerated filer o |
|
Non-accelerated filer o |
|
Smaller reporting company o |
|
|
|
|
|
|
|
|
|
Emerging growth company x |
|
|
|
|
|
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13a) of the Exchange Act. |
|
o |
Item 8.01 Other Events
On July 7, 2017, Emmaus Life Sciences, Inc. (“we,” “us,” “our,” “Emmaus” or the “company”) announced that the United States Food and Drug Administration has approved Endari™ (L-glutamine oral powder) to reduce the severe complications of sickle cell disease in adult and pediatric patients ages 5 and older. A copy of our press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
|
|
Exhibit No. |
|
Description |
|
|
99.1 |
|
Press release dated July 7, 2017 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Date: July 10, 2017 |
EMMAUS LIFE SCIENCES, INC. | |
|
|
| |
|
|
| |
|
|
By: |
/s/ WILLIS C. LEE |
|
|
Name: |
Willis C. Lee |
|
|
Title: |
Chief Financial Officer |